MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. (MPLT): 4 pipeline candidates · 2 upcoming catalysts · ~18 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.7 months
D/E 0.05 · 0% dilution
Lead: Phase 2
4 candidates
2 upcoming, next in ~104d
4 buys · 93 sells (180d)
A transparent, data-derived signal for MapLight Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.3B
Cash
$55.7M
Quarterly Burn
$51.2M
Runway
17.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ml-004/ | Phase 2 |
| ml-007c-ma | Phase 2 |
| ml-007c-ma bid | Phase 2 |
| ml-007c-ma qd | Phase 2 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$402.6M
| Holder | Shares | Value |
|---|---|---|
| novo holdings a/s | 3,686,622 | $74.9M |
| fcpm iii services b.v. | 3,226,400 | $65.6M |
| goldman sachs group inc | 1,994,873 | $40.6M |
| vanguard capital management llc | 1,439,640 | $29.3M |
| blackrock, inc. | 1,339,731 | $27.2M |
| nan fung group holdings ltd | 971,253 | $19.7M |
| pivotal bioventure partners investment advisor llc | 611,447 | $12.4M |
| velan capital investment management lp | 492,893 | $10.0M |
| geode capital management, llc | 481,201 | $9.8M |
| siren, l.l.c. | 450,000 | $9.1M |
Showing top 10 of 77 institutional holders of MapLight Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MapLight Therapeutics, Inc.'s pipeline?
MapLight Therapeutics, Inc. (MPLT) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MapLight Therapeutics, Inc.'s lead drug candidate?
MapLight Therapeutics, Inc.'s most advanced tracked candidate is ml-004/ (Phase 2) for Autism Spectrum Disorder.
What is MapLight Therapeutics, Inc.'s next catalyst?
MapLight Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pipeline candidate" — expected September 30, 2026.
What is MapLight Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MapLight Therapeutics, Inc. has approximately 17.7 months of cash runway.
What is MapLight Therapeutics, Inc.'s market capitalization?
MapLight Therapeutics, Inc.'s market capitalization is approximately $1.3B.
Get the full picture on MapLight Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.